Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug lift depression in obese patients?

NCT ID NCT06707012

Symptom relief Sponsor: Fazaia Ruth Pfau Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding metformin, a common diabetes drug, to standard antidepressants can better improve depression symptoms in obese patients. Researchers will compare two groups of 140 newly diagnosed depressed adults with a BMI over 25: one gets metformin, the other a placebo. The main goal is to see if depression scores drop more with metformin, and they will also check changes in stress-related blood markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, this could point toward a simple, low-cost way to boost depression treatment in people with obesity.
What could go wrong
This is a small, early-phase trial. Metformin is already used for diabetes, but its effect on depression is unproven, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age \>18 to \<45 years * Gender: Both genders (Male and Female) * BMI \>25 * Diagnosis: Newly diagnose cases of depression (mild to severe) * HBA1C: Less than 5.7% (non-diabetic range) Exclusion Criteria: * Existing diabetes * Acute illnesses like acute kidney injury, recent history of myocardial infarction, acute liver injury * Intellectual disabilities or inability to understand due to any reason * Presence of Psychiatric disorders other than depression * Chronic kidney disease (eGFR \< 45 mL/min/1.73 m²). * Use of any psychotropic medication within the past 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression depressive disorder Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fazaia Rurh Pfau Medical College

    RECRUITING

    Karachi, Sindh, 75120, Pakistan

  • Fazaia Ruth Pfau Medical College

    RECRUITING

    Karachi, Sindh, 75120, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.